Biotech News - PDL BioPharma Inc. (Public, NASDAQ:PDLI) -

PDL BioPharma Inc. (Public, NASDAQ:PDLI) -

PDL BioPharma Announces November 2 Webcast of Third Quarter 2006
Financial Results Conference Call

PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI - News) today announced that
it will release its financial results for the third quarter 2006
following the close of the U.S. financial markets on Thursday,
November 2, 2006. PDL will hold a conference call to discuss these
financial results, its commercial and clinical activities and its
forward-looking information and guidance at 4:30 p.m. Eastern time
on November 2, 2006.


A live webcast of the conference call will be available through the
PDL website: www.pdl.com . Please connect to this website at least
15 minutes prior to the live webcast to allow time for any software
download that may be needed to hear the webcast. Financial and
statistical information to be discussed in the call will be
available on the PDL website immediately prior to the commencement
of the call. A replay will be available at www.pdl.com starting
approximately one hour after completion of the webcast.

An audio replay will also be available by telephone from
approximately 6:30 p.m. Eastern time on November 2, 2006 through
6:30 p.m. Eastern time on December 3, 2006. To access the replay,
dial 888-203-1112 from inside the U.S. and 719-457-0820 from outside
the U.S.; enter conference ID number 2444267.

About PDL BioPharma

PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for
severe or life-threatening illnesses. The company currently markets
and sells a portfolio of leading products in the acute-care hospital
setting in the United States and Canada and generates royalties
through licensing agreements with top-tier biotechnology and
pharmaceutical companies based on its pioneering antibody
humanization technology. Currently, PDL's diverse product pipeline
includes investigational compounds in Phase 2 or Phase 3 clinical
development for inflammation and autoimmune diseases, cardiovascular
disorders and cancer. The company's research platform is focused on
the discovery and development of antibodies for the treatment of
cancer and autoimmune diseases. For more information, please see
PDL's website at www.pdl.com .

NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.

---------------------------------------------------------------------
-----------
Source: PDL BioPharma, Inc.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/